Pharma Hemp ®
LABORATORIES

CERTIFICATE OF ANALYSIS No.: 2025-16395

CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8
1000 Ljubljana, Slovenija

SAMPLE *

PHIX THERAPY

Sample condition:	SUITABLE	Work order:	2025-112713	Sample received:	02/04/2025
Sample ID:	2514016	Analysis ID:	2025_107	Start of analysis:	02/04/2025
Sample type:	Paste	Method ID:	PHL_RPC_16C	End of analysis:	02/04/2025
Batch No.: *	20250327	Method SOP:	MET-LAB-001-08	Analyst:	Valentina Malin

* Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	4.72	0.24	
CBDA	- Cannabidiolic acid	0.400	0.068	
CBGA	- Cannabigerolic acid	< LOQ	n/a	
CBG	- Cannabigerol	30.6	2.1	
CBD	- Cannabidiol	30.3	1.5	
THCV	- Tetrahydrocannabivarin	1.106	0.055	
CBN	- Cannabinol	< LOQ	n/a	
Δ^9-THC	- Δ-9-Tetrahydrocannabinol	0.067	0.015	
Δ^8-THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL	- Cannabicyclol	< LOQ	n/a	
CBC	- Cannabichromene	< LOQ	n/a	
Δ^9-THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
CBV	- Cannabivarin	0.133	0.023	
CBCA	- Cannabichromenic acid	< LOQ	n/a	
CBT	- Cannabicitran	< LOQ	n/a	
CBE	- Cannabielsoin	0.253	0.058	

<u>Units and abbreviations</u>: **% w/w** = weight percent, **< LOQ** = below the limit of quantitation (0.03 % w/w), **ND** = not detected, **n/a** = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

02/04/2025

_____

End of Certificate

Approved by:

_____
mag. Valentina Malin
Analytical Laboratory Manager

Authorized by:

_____
dr. Boštjan Jančar
Chief Technology Officer